Earlier this month, our Chief Operating Officer and Chief Business Officer, Dr Glenn Corr, presented at the London Stock Exchange’s Future of Healthcare Investment Forum.
Glenn provided an overview of the company, its fundraising history, and shared insights on our latest research supporting our mission to develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative diseases such as Alzheimer’s.
Discussing the growing prevalence of Alzheimer’s, Glenn explained the urgent need for new disease-modifying treatments that have potential to halt disease progression or, better still, prevent symptoms from ever developing by tackling the key underlying pathologies that start years before symptoms manifest. With advancing diagnostics and breakthroughs in how healthcare systems manage patients, this is becoming a more realistic target for industry.
As one of many companies seeking to treat Alzheimer’s and related neurodegenerative diseases with a safe and accessible drug, what sets TauRx apart is the team’s dedicated focus on the tau pathology and the misfolding of tau as a key target for an effective therapy.
Tau is a critical protein for the normal function of brain cells with a very important role in stabilising the structure of neurons and facilitating cell communication in the brain.
However, ‘tau tangles’, which form inside brain cells when tau protein misfolds and aggregates, cause brain cell death and the irreversible damage associated with clinical dementia. Our lead compound is designed to interfere with this process and prevent the progression of disease.
TauRx’s research and strategy is well supported and allowed the company to secure additional investment of USD119 million through a warrants exercise in late 2022 allowing regulatory progress and pursuit of our go-to market strategy.
TauRx was granted an Innovation Passport by the UK Medicines & Healthcare products Regulatory Agency (MHRA) in May 2022. This passport is the first stage of the Innovative Licensing and Access Pathway (ILAP), which is intended to accelerate development and approval times, facilitating access to new products and indications.
Find out more about TauRx, here.
